ES2190139T3 - Inhibidor de la angiogenesis. - Google Patents

Inhibidor de la angiogenesis.

Info

Publication number
ES2190139T3
ES2190139T3 ES99102501T ES99102501T ES2190139T3 ES 2190139 T3 ES2190139 T3 ES 2190139T3 ES 99102501 T ES99102501 T ES 99102501T ES 99102501 T ES99102501 T ES 99102501T ES 2190139 T3 ES2190139 T3 ES 2190139T3
Authority
ES
Spain
Prior art keywords
compounds
angiogenesis
proteasa
inflammation
represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99102501T
Other languages
English (en)
Inventor
Chiho Fukiage
Mitsuyoshi Azuma
Jun Inoue
Masayuki Nakamura
Yuka Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2190139T3 publication Critical patent/ES2190139T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/48—Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN INHIBIDOR DE ANGIOGENESIS QUE COMPRENDE UN COMPUESTO INHIBIDOR DE LA CISTEINA PROTEASA. PUEDEN UTILIZARSE COMO COMPUESTOS INHIBIDORES DE LA CISTEINA PROTEASA PREFERIDOS, COMPUESTOS DE ACIDO EPOXISUCCINICO, COMPUESTOS PEPTIDICOS DE HALOHIDRAZIDA, COMPUESTOS INHIBIDORES DE CALPAINA, COMPUESTOS QUE SE REPRESENTAN POR LA FORMULA (I): Y COMPUESTOS REPRESENTADOS POR LA FORMULA (VI): DICHO INHIBIDOR DE ANGIOGENESIS SUPRIME LA NUEVA FORMACION DE VASOS SANGUINEOS EN LOS TEJIDOS VIVOS, DE TAL MODO QUE PUEDE UTILIZARSE COMO AGENTE PROFILACTICO O TERAPEUTICO SUPERIOR DE LA ANGIOGENESIS ASOCIADA CON LA CICATRIZACION DE HERIDAS, INFLAMACION, CRECIMIENTO DE TUMORES Y SIMILARES, Y DE LA ANGIOGENESIS QUE ACOMPAÑA A LA RETINOPATIA DIABETICA, RETINOPATIA PREMATURA, OCLUSION VENOSA RETINIANA, DEGENERACION MACULAR DISCOIDE SENIL Y SIMILARES, ASI COMO PARA LA PREVENCION DE METASTASIS DE TUMORES.
ES99102501T 1995-10-25 1996-10-23 Inhibidor de la angiogenesis. Expired - Lifetime ES2190139T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP27748595 1995-10-25
JP24804696 1996-09-19

Publications (1)

Publication Number Publication Date
ES2190139T3 true ES2190139T3 (es) 2003-07-16

Family

ID=26538555

Family Applications (2)

Application Number Title Priority Date Filing Date
ES99106760T Expired - Lifetime ES2193615T3 (es) 1995-10-25 1996-10-23 .nhibidor de la angiogenesis.
ES99102501T Expired - Lifetime ES2190139T3 (es) 1995-10-25 1996-10-23 Inhibidor de la angiogenesis.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES99106760T Expired - Lifetime ES2193615T3 (es) 1995-10-25 1996-10-23 .nhibidor de la angiogenesis.

Country Status (13)

Country Link
US (2) US6057290A (es)
EP (2) EP0927716B1 (es)
AR (1) AR004694A1 (es)
AT (3) ATE239698T1 (es)
AU (1) AU716495B2 (es)
BR (1) BR9605267A (es)
CA (1) CA2188817C (es)
DE (3) DE69625622T2 (es)
ES (2) ES2193615T3 (es)
HU (1) HUP9602943A3 (es)
MX (1) MX9605156A (es)
NO (1) NO964514L (es)
PL (1) PL316669A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1195343A (zh) * 1995-07-13 1998-10-07 千寿制药株式会社 哌啶衍生物及其用途
US6214800B1 (en) * 1995-10-25 2001-04-10 Senju Pharmaceutical Co., Ltd. Angiogenesis inhibitor
DE19718826A1 (de) * 1997-05-05 1998-11-12 Marion S Dr Eckmiller Verwendung biologisch aktiver Wirkstoffe zum Beeinflussen des Extrazellulär-Raumes von Sinneszellen und Verfahren zur Wirkstoff-Administrationssteuerung
EP1342720A3 (en) * 1997-09-04 2004-02-11 Nippon Chemiphar Co., Ltd. Epoxysuccinamide derivatives
US6015787A (en) * 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
AU2745599A (en) 1998-03-05 1999-09-20 Senju Pharmaceutical Co., Ltd. Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy
DE69919995T2 (de) 1998-03-20 2005-09-22 Senju Pharmaceutical Co., Ltd. Verwendung von cysteinprotease inhibitoren zur herstellung eines arzneimittels zur vorgbeugung und behandlung von gehirngewebezerrütung infolge hypertensive enzephalopathie oder encephalothlipsis
GB9819860D0 (en) * 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
AU2592600A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
AU3196300A (en) * 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Carbocyclic sulfonamide derivatives
KR20010001270A (ko) * 1999-06-03 2001-01-05 복성해 혈관신생을 억제하는 새로운 이소쿠마린 유도체
US7052714B1 (en) 1999-10-13 2006-05-30 Senju Pharmaceutical Co., Ltd Ophthalmic adhesive preparations for percutaneous adsorption
AU1735001A (en) * 1999-12-10 2001-06-18 Senju Pharmaceutical Co., Ltd. Cyclodextrin-containing pharmaceutical composition
JPWO2002034252A1 (ja) * 2000-10-26 2004-03-04 千寿製薬株式会社 ジペプチジルアルデヒド誘導体含有医薬組成物
WO2002048096A1 (en) * 2000-12-12 2002-06-20 Senju Pharmaceutical Co., Ltd. Hydrazone derivatives and use thereof in medicines
US7183320B2 (en) 2001-06-06 2007-02-27 Eli Lilly And Company Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
US7115607B2 (en) * 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
JPWO2003078415A1 (ja) * 2002-03-15 2005-07-14 千寿製薬株式会社 環状ヘミアセタール誘導体およびその用途
ATE473216T1 (de) * 2002-03-29 2010-07-15 Senju Pharma Co Hydroxymorpholinonderivat und dessen medizinische verwendung
EP1354586A1 (en) * 2002-04-20 2003-10-22 Aventis Pharma Deutschland GmbH The use of hydroxpyridone-derivatives in wound healing
AU2003248059A1 (en) 2002-07-22 2004-02-09 Senju Pharmaceutical Co., Ltd. NOVEL Alpha-KETOAMIDE DERIVATIVE AND USE THEREOF
GB0314262D0 (en) 2003-06-19 2003-07-23 Univ Nottingham Trent Novel compounds and methods of using the same
US7615556B2 (en) * 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
US8236798B2 (en) 2009-05-07 2012-08-07 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
WO2011105070A1 (ja) 2010-02-25 2011-09-01 パナソニック株式会社 需給制御装置、需給制御方法、およびプログラム
JP5823484B2 (ja) 2010-07-14 2015-11-25 千寿製薬株式会社 α―ケトアミド誘導体固体分散体
GB201218084D0 (en) * 2012-10-09 2012-11-21 Univ Aston Novel compounds and methods for use in medicine
GB201220474D0 (en) * 2012-11-14 2012-12-26 Sagetis Biotech Sl Polypeptides
US20210145930A1 (en) * 2018-05-07 2021-05-20 NeuroTheranostics, Inc. Multiple layer article with interactive reinforcements linear ribbon fiber reinforcement for composite forms
WO2022187491A1 (en) * 2021-03-03 2022-09-09 The Texas A& M University System Inhibitors of cysteine proteases

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50137951A (es) 1974-04-27 1975-11-01
JPS5754157A (en) 1980-09-19 1982-03-31 Nippon Kayaku Co Ltd L-argininal derivative and its preparation
PT84170B (pt) * 1986-01-24 1989-03-30 Sanofi Sa Processo para a preparacao de derivados n alfa-substituidos das n alfa-aril-sulfonilaminoacil d-amidinofenil-alaninamidas
JPH0832698B2 (ja) * 1987-05-08 1996-03-29 日本ケミファ株式会社 ピペラジン誘導体
JP2536754B2 (ja) * 1987-05-08 1996-09-18 日本ケミファ株式会社 ピペラジン誘導体
US5510531A (en) 1989-04-10 1996-04-23 Suntory Limited Proteinase inhibitor
JP2701932B2 (ja) * 1989-04-10 1998-01-21 サントリー株式会社 タンパク質分解酵素阻害剤
EP0395309B1 (en) * 1989-04-28 1995-12-27 Takara Shuzo Co. Ltd. Human calpastatin-like polypeptide
EP0572547A1 (en) 1991-02-22 1993-12-08 The Du Pont Merck Pharmaceutical Company SUBSTITUTED $g(a)-AMINOALDEHYDES AND DERIVATIVES
EP0504938A3 (en) * 1991-03-22 1993-04-14 Suntory Limited Prophylactic and therapeutic agent for bone diseases comprising di- or tripeptide derivative as active ingredient
CA2071621C (en) * 1991-06-19 1996-08-06 Ahihiko Hosoda Aldehyde derivatives
JP2848232B2 (ja) 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
US5607831A (en) 1993-03-25 1997-03-04 The United States Of America As Represented By The Department Of Health And Human Services In vitro methods for assessing the susceptibility of HIV-1-infected individuals to cysteine protease-mediated activation-induced programmed cell death
US5658885A (en) 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
JP3599287B2 (ja) * 1993-04-28 2004-12-08 三菱化学株式会社 スルホンアミド誘導体
AU3534195A (en) * 1994-09-27 1996-04-19 Takeda Chemical Industries Ltd. Aldehyde derivatives as upsteine protease inhibitors
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
EP0731107A1 (en) * 1995-02-13 1996-09-11 Takeda Chemical Industries, Ltd. Production of aldehyde derivatives
EP0824543A1 (en) 1995-05-10 1998-02-25 Chiroscience Limited Peptide compounds which inhibit metalloproteinase and tnf liberation, and their therapeutic use
CN1195343A (zh) * 1995-07-13 1998-10-07 千寿制药株式会社 哌啶衍生物及其用途
ATE377006T1 (de) 1995-11-28 2007-11-15 Cephalon Inc Aus d-aminosäuren abgeleitete cystein- und serinproteasehemmer

Also Published As

Publication number Publication date
US6057290A (en) 2000-05-02
DE69625622T2 (de) 2003-08-14
CA2188817A1 (en) 1997-04-26
EP0927716A1 (en) 1999-07-07
AU7038496A (en) 1997-05-01
PL316669A1 (en) 1997-04-28
EP0927716B1 (en) 2003-05-07
EP0771565A3 (en) 1998-11-04
NO964514D0 (no) 1996-10-24
DE69628050T2 (de) 2004-04-01
EP0771565B1 (en) 2003-01-02
DE69625575D1 (de) 2003-02-06
HUP9602943A3 (en) 1998-03-02
DE69628050D1 (de) 2003-06-12
NO964514L (no) 1997-04-28
EP0771565A2 (en) 1997-05-07
MX9605156A (es) 1998-05-31
BR9605267A (pt) 1998-07-21
ATE230275T1 (de) 2003-01-15
ATE230389T1 (de) 2003-01-15
DE69625622D1 (de) 2003-02-06
AU716495B2 (en) 2000-02-24
US6551999B1 (en) 2003-04-22
ATE239698T1 (de) 2003-05-15
ES2193615T3 (es) 2003-11-01
HUP9602943A2 (en) 1997-08-28
CA2188817C (en) 2010-01-26
DE69625575T2 (de) 2003-09-25
AR004694A1 (es) 1999-03-10

Similar Documents

Publication Publication Date Title
ES2190139T3 (es) Inhibidor de la angiogenesis.
DE60110054D1 (en) Cardioprotektive phosphonate
DE69401204D1 (de) Gonadotropin enthaltende gefriergetrocknete troepfen
MXPA03006855A (es) Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol, utilizando acido 3,5-diyodotiropropionico, y metodo para su preparacion.
ES2170305T3 (es) Derivados de acido hidroxietilaminosulfamico n-sustituidos utiles como inhibidores de proteasas retroviricas.
DK0460062T3 (da) Huperzin A-analoger
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
CO4960655A1 (es) Nueva composicion y su uso
DK0477274T3 (da) Faktor Xa baserede antikoaguleringspræparater
AR018357A1 (es) Acido petroselinico en una composicion y en un metodo para reducir o eliminar la irritacion o la picazon de la piel inducida por los alfa-hidroxiacidos
ATE223398T1 (de) Polyoxypropylenpolyoxyethylen-vitamin e und seine herstellung
ATE202483T1 (de) Immuntolerante prothrombinkomplex-präparation
BR0200773A (pt) Produtos de celulose modificados por um ligando
ES2111032T5 (es) Carboxialquil polisacaridos y procedimiento de fabricacion de los mismos.
ATE309796T1 (de) Verfahren zur behandlung von augenerkrankungen
ATE220912T1 (de) Herstellung von st1435 enthaltenden pharmazeutischen zusammensetzungen zur topischen verwendung
HUP0301864A2 (hu) Fenoláttartalmú, alacsony fagyáspontú készítmény
ES2089286T3 (es) Nuevas 2-amino-5-ciano-1,4-dihidropiridinas, procedimiento para su preparacion y su uso en medicamentos.
ES2108364T3 (es) Composiciones azeotropicas que comprenden agua y un hidrofluorocarburo, procedimiento de eliminacion de agua de una solucion por destilacion azeotropica y procedimiento de produccion de un hidrofluoroalcano.
BR0009194A (pt) Composição do resorcinol
HN2001000204A (es) Amidas de acido fenilciclohexanocarboxilico sustituido y su uso
TW332205B (en) A process for making a clinically efficacious HIV protease inhibitor eliminates one step in its synthesis, by an alternative convergent synthesis using 2(S)-4-picolyl-2-piperazine-t-butyl-carboxamide as an intermediate.
ES2120966T3 (es) 1'-aminoespiro(isoquinolino-4(1h),3'-pirrolidino)-1,2',3,5'(2h)-tetronas y analogos de las mismas utiles como inhibidores de la aldosa reductasa in vivo.
ES2132726T3 (es) Agente acuoso para el fregado a mano de la vajilla.
MX9603133A (es) Acido para hidroxifenilacetico para la reduccion de la repelencia de insecticidas.